Welcome to our dedicated page for BIO-PATH HOLDINGS news (Ticker: BPTH), a resource for investors and traders seeking the latest updates and insights on BIO-PATH HOLDINGS stock.
Bio-Path Holdings develops targeted nucleic acid drug candidates using its DNAbilize® liposomal delivery and antisense RNAi nanoparticle technology. Its disclosed pipeline includes prexigebersen (BP1001), which targets Grb2 for blood cancers; BP1001-A, a modified prexigebersen candidate studied in solid tumors and metabolic disease models; BP1002, which targets Bcl-2 for blood cancers and solid tumors; and a STAT3 antisense program.
Company news commonly covers clinical and preclinical program updates, obesity and Type 2 diabetes research, acute myeloid leukemia and other oncology studies, patent grants tied to DNAbilize®, financial results, investor presentations, and corporate or operational updates affecting the biotechnology portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.